
æ°åã³ããã¯ã¯ãã³ãšããªãªã³ç ã®ãªã¹ã¯
6/16æŽæ°ã远èšããã
---
æåŸã«ããã ãã¯èšãããŠãã ããã
çµè«ããå
ã«èšãã°ããmRNAã¯ã¯ãã³æ¥çš®ãããªãªã³ç
ãåŒãèµ·ãããšããæç¢ºãªç§åŠçæ ¹æ ã¯ãããŸãããã
æ¥æ¬ã§ã¯ã8å²è¿ãã®äººãå¿ èŠåæ°ã®ã¯ã¯ãã³æ¥çš®ãæžãŸããä»ãè¡ãæ©ã倧倿°ãã¯ã¯ãã³æ¥çš®è ã§ãããã®äžã«ã¯ãmRNAã¯ã¯ãã³æ¥çš®ã®ãªã¹ã¯ãšãããã£ãããåæ¡ããã«ã»ãããã¯ã§ããã«ãåŠæ ¡ãè·å Žã§ã®å匷å¶ããåšããæ¥çš®ããŠãããããšããçç±ã§æ¥çš®ãã人ãããã§ãããã
çŸåšãTwitterãnoteã«ã¯ãä»å玹ä»ãããããªãªã³ä»®èª¬ããã¯ãããšãããæã話ããããµããŠããŸãããã®ãããªè©±é¡ã®äžå¿ã«ããã®ã¯ãã¯ã¯ãã³ãæ¥çš®ããŠããªã人ãã¡ã§ãããããã®ãæã話ãã«ééã¯ãªããã¯ã¯ãã³ãæ¥çš®ããããšãé ·ãåŸæããããããªããšãèšã人ãããŸãã
ããããªããããã®ãæã話ãã¯ãæ£ããç§åŠçæ ¹æ ã«åºã¥ããŠããã®ã§ããããïŒ
ä»åã¯ãmRNAã¯ã¯ãã³ã«é¢ãããæã話ãã®äžã§ããæ°å¹ŽåŸã«çºç ãããããããªããããæ²»çæ³ããªãããšãã£ãç¹ãããç§ãæãæããšæãããããªãªã³ä»®èª¬ãã«ã€ããŠããŸã äžæžãç¶æ ã®ãã®ã«ãªããŸããããŸãšãããšãããŸã§ãäžã€ã®èšäºãšããŠå ¬éãããŠããã ããŸãã
ç§ã¯Twitterãšnoteã«ãããæŽ»åãæ¢ããŸãããæ¢ã«ã¯ã¯ãã³ãæ¥çš®ãããæ¹ã®ããšã ããæ¬åœã«æ°æããã§ããã©ãããããªãªã³ä»®èª¬ãã®ãããªèšèª¬ãèŠèãããŠããé床ã«äžå®ã«ãªããªãããã«ããŠãã ãããäžå®ãªå¿ã¯å¥åº·ã害ããŸãã
â» ãã®èšäºã¯å人ã®èŠè§£ã§ãããæå±æ©é¢ã代衚ãããã®ã§ã¯ãããŸããã
â»Â ãã®èšäºã«ç¹å®ã®å人ãå£äœãè²¶ããæå³ã¯ãããŸããã
â»Â æè²¬ã¯ãå
šãŠç¿¡ç¿ å人ã«ãããŸãã
â»Â ãã³ããã®åçã ãã§ã¯äžå®ãªæ¹ã¯ããã²èªãã§ãã ããã

ïŒç»åïŒhttps://covnavi.jp/wp-content/themes/covnavi/img/data_Mythbusters.pdfïŒ
---
以äžããããªãªã³ä»®èª¬ãã®æ ¹æ è«æãšããŠèåãª2ã€ã®è«æã玹ä»ã»è§£èª¬ããŸãã
---
J.ããŒãã»ã¯ã©ãã»ã³ïŒJ. Bart ClassenïŒã®è«æ



Microbiology & Infectious Diseases
COVID-19 RNA Based Vaccines and the Risk of Prion Disease
èš³ïŒCOVID-19 RNAããŒã¹ã®ã¯ã¯ãã³ãšããªãªã³ç ã®ãªã¹ã¯
J. Bart Classen
https://scivisionpub.com/pdfs/covid19-rna-based-vaccines-and-the-risk-of-prion-disease-1503.pdf
çµæïŒResultsïŒããåŒçšã
Analysis of the Pfizer vaccine against COVID-19 identified two potential risk factors for inducing prion disease is humans. The RNA sequence in the vaccine [3] contains sequences believed to induce TDP-43 and FUS to aggregate in their prion based conformation leading to the development of common neurodegerative diseases.
èš³ïŒCOVID-19ã«å¯Ÿãããã¡ã€ã¶ãŒç€Ÿã®mRNAã¯ã¯ãã³ãè§£æããçµæãããã«ããªãªã³ç ãèªçºãã2ã€ã®æœåšçãªãªã¹ã¯èŠå ã倿ããŸãããã¯ã¯ãã³ã«å«ãŸããRNA [3]ã«ã¯ãTDP-43ã¿ã³ãã¯è³ªãšFUSã¿ã³ãã¯è³ªããããªãªã³ã«åºã¥ãæ§é ã§åéããããã«èªå°ãããšèããããé åãå«ãŸããŠãããäžè¬çãªç¥çµå€æ§çŸæ£ã®çºçã«ã€ãªãããšèããããŸãã
https://www.scivisionpub.com/abstract-display.php?id=1503
è«æã§ç»å Žãã2ã€ã®ã¿ã³ãã¯è³ªã«é¢ãã説æãâ
ãTDP-43ã¿ã³ãã¯è³ªã
414ã€ã®ã¢ããé žãããªããå€ãã®çµç¹ã»çްèã§æåžžçã«çºçŸããRNAçµåã¿ã³ãã¯è³ªã§ããã现èå ã§ã¯äž»ãšããŠæ žã«ååšããããæ žå€ãæ žå ç§»è¡ã·ã°ãã«ãã¢ããé žé åã«æããŠãããããæ žãšçްè質ãšã®éãåŸæ¥ããŠããã翻蚳å¶åŸ¡ãã¹ãã©ã€ã·ã³ã°å¶åŸ¡ãªã©ãã¯ãããšããå€é¢çãªRNAå¶åŸ¡ãè¡ãªããšèããããŠããã2006幎ã«TDP-43ã¿ã³ãã¯è³ªãALSïŒçèçž®æ§åŽçŽ¢ç¡¬åçïŒãåé åŽé è倿§çã®ç å·£ã«ç°åžžèç©ããããšã倿ããåŸã«TDP-43éºäŒåã®å€ç°ãäžéšã®éºäŒæ§ALSã§ã¿ãããããšãããTDP-43ã¿ã³ãã¯è³ªã®ç°åžžããALSã®çºçã«é¢ããéèŠãªå åã§ãããšèããããŠããã
https://www.riken.jp/press/2012/20121218/index.html
ãFUSã¿ã³ãã¯è³ªã
Fused in sarcoma (FUS)ã¯TLS(translocated in liposarcoma)ãšãç§°ãããRNAçµåã¿ã³ãã¯è³ªã§ãäž»ãšããŠæ žå ã«å±åšã転åãéžæçã¹ãã©ã€ã·ã³ã°ãRNA茞éãªã©RNA代è¬å šè¬ã«æ©èœããååã§ãããChopãªã©ãšã®èåã¿ã³ãã¯è³ªãçã®åå éºäŒåãšãªãããšã§çºèŠããåœåãããããè¿å¹Žã¯çèçž®æ§åŽçŽ¢ç¡¬åçïŒALSïŒã®åå éºäŒåããã³ç æ é¢é£ååãšããŠæ³šç®ãããŠããã
https://bsd.neuroinf.jp/wiki/Fused_in_sarcoma
è«æã®çµæïŒResultsïŒã®ç¶ããâ
In particular it has been shown that RNA sequences GGUA [4], UG rich sequences [5], UG tandem repeats [6], and G Quadruplex sequences [7], have increased affinity to bind TDP-43 and or FUS and may cause TDP-43 or FUS to take their pathologic configurations in the cytoplasm. In the current analysis a total of sixteen UG tandem repeats (ΚGΚG) were identified and additional UG (ΚG) rich sequences were identified. Two GGΚA sequences were found. G Quadruplex sequences are possibly present but sophisticated computer programs are needed to verify these.
èš³ïŒç¹ã«ãRNAã®é åã®ãã¡ãGGUA[4]ãUGãªããé å[5]ãUGã¿ã³ãã ãªããŒã[6]ãã°ã¢ãã³ïŒGïŒåééæ§é [7]ã¯ãTDP-43ãFUSãšã®èŠªåæ§ãé«ããTDP-43ãFUSã现è質å ã§ç çãªåœ¢æ ããšãåå ã«ãªããšèããããŠããŸããä»åã®è§£æã§ã¯ãåèš16åã®UGã¿ã³ãã ãªããŒãïŒÎšGΚGïŒãšãããã«UGïŒÎšGïŒãªãããªé åãåå®ãããGGΚAé åã2ã¶æèŠã€ãããŸãããGåééæ§é ãååšããå¯èœæ§ããããŸããããããæ€èšŒããã«ã¯é«åºŠãªã³ã³ãã¥ãŒã¿ããã°ã©ã ãå¿ èŠã§ãã
https://www.scivisionpub.com/abstract-display.php?id=1503
J.ããŒãã»ã¯ã©ãã»ã³ã¯ããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®mRNAã«ãGGUAãããUGãªããé
åãããUGã¿ã³ãã ãªããŒããããGåééé
åããšåŒã°ããç¹æ®ãªé
åãååšããããšãããããã«TDP-43ã¿ã³ãã¯è³ªãFUSã¿ã³ãã¯è³ªãçµåããç¥çµå€æ§çŸæ£çºçã®åå ã«ãªããããããªãããšäž»åŒµããŠãããâïŒãã ããGGUAã¯ãæ£ç¢ºã«ã¯ãGGUAAGUãã§ãTAF15ãšããFUSã¿ã³ãã¯è³ªã«äŒŒãå¥ã®RNAçµåã¿ã³ãã¯è³ªãçµåããé
åãïŒ

ãã¡ã€ã¶ãŒç€Ÿã®mRNAã¯ã¯ãã³ã«å«ãŸããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®mRNAïŒä»¥åŸãæ£åŒåç§°ãTozinameranããšè¡šèšïŒã®é
åãâ

[販 売 å] ã³ãããã£ç泚
[äž è¬ å] ã³ãããŠã€ã«ã¹ä¿®é£ŸãŠãªãžã³RNAã¯ã¯ãã³(SARS-CoV-2)
(æå¹æåå:ããžãã¡ã©ã³)
[ç³è«è å] ãã¡ã€ã¶ãŒæ ªåŒäŒç€Ÿ
https://www.mhlw.go.jp/content/10601000/000739137.pdf
Κã¯ããŠãªãžã³ïŒUïŒãšçœ®ãæãããããã·ã¥ãŒããŠãªãžã³ãã瀺ããŠããã
Tozinameranã®å
šé·4284å¡©åºã®äžã«ã¯ããUGUGïŒÎšGΚGïŒãã19åïŒå³äžèµ€æåïŒããGGUAïŒGGΚAïŒãã4åïŒå³äžéæåïŒååšãããâ

J.ããŒãã»ã¯ã©ãã»ã³ã®è§£æçµæã¯ééããâ
ä»åã®è§£æã§ãåèš16åã®UGã¿ã³ãã ãªããŒãïŒÎšGΚGïŒãšãããã«UGïŒÎšGïŒãªãããªé åãåå®ãããGGΚAé åã2ã¶æèŠã€ãããŸããã
https://www.scivisionpub.com/abstract-display.php?id=1503
粟補ããTDP-43ã¿ã³ãã¯è³ªã¯ã3åã®ãUGãªããŒãïŒUGUGUGïŒãã«å¯Ÿãããã€ã¯ãã¢ãŒã©ãŒïŒÎŒMïŒãªãŒããŒã§åŒ±ãçµåããããšãå ±åãããŠãããïŒãUGãã4, 6, 8åãšå¢ããæ¯ã«ãçµååã¯1ãªãŒããŒãã€å¢å ãããïŒâ

Nucleic Acids Res. 2009 Apr;37(6):1799-808. doi: 10.1093/nar/gkp013. Epub 2009 Jan 27.
Structural insights into TDP-43 in nucleic-acid binding and domain interactions
https://academic.oup.com/nar/article/37/6/1799/1029648
åæ§ã®ç²Ÿè£œããTDP-43ã¿ã³ãã¯è³ªïŒGST-TDP43ïŒãçšããå®éšã§ãTDP-43ã¿ã³ãã¯è³ªãçµåããããã«ã¯ãmRNAäžã«æå°6åã®UGãªããŒãïŒUGUGUGUGUGUGïŒãå¿ èŠã§ãããšããå ±åããããâ
J Biol Chem. 2001 Sep 28;276(39):36337-43. doi: 10.1074/jbc.M104236200. Epub 2001 Jul 24.
Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9
https://www.sciencedirect.com/science/article/pii/S0021925820867064?via%3Dihub
ããã®è³å ã§ãå®éã«TDP-43ã¿ã³ãã¯è³ªãçµåããããšãæããã«ãªã£ãŠãããUGã¿ã³ãã ãªããŒãããšãUGãªããé åãã®äŸïŒå³äžèµ€å²ã¿ïŒãïŒããªãããïŒè±å¯ã«ãããã®ã®æïŒâ

ïŒç»åïŒhttps://www.nature.com/articles/nn.2778/figures/1ïŒ
Nat Neurosci. 2011 Apr;14(4):452-8. doi: 10.1038/nn.2778. Epub 2011 Feb 27.
Characterizing the RNA targets and position-dependent splicing regulation by TDP-43
https://www.nature.com/articles/nn.2778
ãã®ãããªé
åã¯ãTozinameranã®é
åäžã«ååšããªãã
TAF15ã¿ã³ãã¯è³ªïŒFUSã¿ã³ãã¯è³ªãšåãFETã¿ã³ãã¯è³ªãã¡ããªãŒã«åé¡ãããã¿ã³ãã¯è³ªïŒãçµåãããGGUAAGUïŒGGΚAAGΚïŒãã¯ãTozinameranã®é åäžã«ååšããªãã

ïŒç»åïŒhttps://www.nature.com/articles/ncomms12143/figures/1ïŒ
FUSã¿ã³ãã¯è³ªãçµåãããã°ã¢ãã³ïŒGïŒåééæ§é ããäºæž¬ããããšã¯å°é£ã
Gåééæ§é ãååšããå¯èœæ§ããããŸããããããæ€èšŒããã«ã¯é«åºŠãªã³ã³ãã¥ãŒã¿ããã°ã©ã ãå¿ èŠã§ãã
https://www.scivisionpub.com/abstract-display.php?id=1503
ããããªããã4åã®ãGGGããšãã®éã«1~7åã®å¡©åºãå«ãé
åããåäžå¹³é¢äžã«4æ¬ã®éãéãŸã£ãç¹æ®ãªæ§é ïŒïŒãGåééæ§é ããG4ãšãåŒã°ããïŒã圢æããããšãç¥ãããŠãããâ

ïŒç»åïŒhttps://www.ueharazaidan.or.jp/houkokushu/Vol.32/pdf/report/186_report.pdfïŒ
Tozinameranã®äžã«ãGåééæ§é ã圢æããããã«å¿ èŠãª4åã®ãGGGããšãã®éã«1~7åã®å¡©åºãå«ãé åã¯ååšããªããâ

çµè«ïŒTozinameranã«ãæ¢ç¥ã®TDP-43ã¿ã³ãã¯è³ªãFUSã¿ã³ãã¯è³ªïŒTAF15ã¿ã³ãã¯è³ªïŒãçµåããããšã瀺åããé åã¯ååšããªãã£ãã
---
å人çãªèŠè§£ïŒãã®è«æã®æå€§ã®åé¡ç¹ã¯ããUGUGïŒÎšGΚGïŒããšãGGUAïŒGGΚAïŒãã®æ°ãééããããããšãäžè¬çãªåŠè¡è«æãããã§ããããã«ãè§£æçµæãå³ç€ºããã°ããã®ãããªã€ãŒãžãŒãã¹ãé²ãããšãã§ãããããããªãã
Microbiology & Infectious Diseasesã«æ²èŒããããæ»èªä»ãè«æãã§ãããšããããšã«å¯ŸããŠãçåãæ®ãè«æã§ãã£ãã
---
George TetzãšVictor Tetzã®è«æ

Preprints 2020, 2020030422 (doi: 10.20944/preprints202003.0422.v1).
SARS-CoV-2 Prion-Like Domains in Spike Proteins Enable Higher Affinity to ACE2
èš³ïŒSARS-CoV-2ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã«ååšããããªãªã³-likeïŒããªãªã³æ§ïŒãã¡ã€ã³ã¯ãå容äœACE2ãšã®èŠªåæ§ãé«ããå¯èœæ§ãããã
George Tetz and Victor Tetz
https://www.preprints.org/manuscript/202003.0422/v1
ãã®ãããïŒTetzïŒãã®è«æã§ã¯ãç®çã®ã¿ã³ãã¯è³ªãšããªãªã³ã¿ã³ãã¯è³ªãšã®é¡äŒŒæ§ãè©äŸ¡ããããããPLAACïŒPrion-Like Amino Acid Composition ïŒããšãããœãããŠã§ã¢ã䜿ã£ãè§£æãè¡ãããã

PLAACïŒPrion-Like Amino Acid Composition ïŒ
http://plaac.wi.mit.edu
Identification of PrDs in viral proteomes
The presence of PrDs in β-CoV proteomes found using the PLAAC algorithm and the output probabilities for the PrDs were constructed based on amino-acid frequencies and similarities with PrDs in Saccharomyces cerevisiae.
https://www.preprints.org/manuscript/202003.0422/v1
ãã®ãœãããŠã§ã¢ã®è©³çްãâ
Bioinformatics. 2014 Sep 1;30(17):2501-2. doi: 10.1093/bioinformatics/btu310. Epub 2014 May 13.
PLAAC: a web and command-line application to identify proteins with prion-like amino acid composition
https://academic.oup.com/bioinformatics/article/30/17/2501/2748168
詊ãã«ãããªãªã³ã¿ã³ãã¯è³ªãã®ãã®ãPLAACã§è§£æããã
ããªãªã³ã¿ã³ãã¯è³ªã¯ã253åã®ã¢ããé
žãããªãå°ããªã¿ã³ãã¯è³ªãâ
>BAG32276.1 prion [Homo sapiens]
MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPSKPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYYRENMHRYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERVVEQMCITQYERESQAYYQRGSSMVLFSSPPVILLISFLIFLIVG
https://www.ncbi.nlm.nih.gov/protein/BAG32276.1

ïŒç»åïŒhttps://www.thermofisher.com/blog/food/prion-disease-and-the-safety-of-our-food-supply/ïŒ
ããªãªã³ã¿ã³ãã¯è³ªããç°åžžåããªãªã³ã¿ã³ãã¯è³ªïŒPrPSCïŒãã«çµåãããšãæ£åžžåã®ããªãªã³ã¿ã³ãã¯è³ªãé£éçã«ç°åžžåã«å€æãããããªãªã³ç
ãé²è¡ãããšèããããŠããã

ïŒç»åïŒhttp://virology.biken.osaka-u.ac.jp/old2/public_html/prion.htmlïŒ
ã¢ããé žé åãèŠããšããGXXXGïŒã°ãªã·ã³ïŒGïŒãšããã¢ããé žã®éã«3ã€ã®ä»»æã®ã¢ããé žãå«ãŸããé åïŒããšãããããªãªã³ã¿ã³ãã¯è³ªãšããŠã®æ§è³ªãç¹åŸŽä»ããé åïŒïŒã¢ããŒãïŒããååéšåã«éãªããªãã倧éã«ååšããã

PLAACãããããŒãžã®ç©ºæ¬ã«ãããªãªã³ã¿ã³ãã¯è³ªã®ã¢ããé žé åãã³ããããã

ïŒç»åïŒhttp://plaac.wi.mit.eduïŒ
å ¥åããããå³äžã®éè²ã®ãã¿ã³ãRun Analysisããã¯ãªãã¯ããã
è§£æçµæãâ

äžçªäžã«è¡šç€ºãããã°ã©ãã®æšªè»žã¯ã巊端ãå
é ã«çš®é¡æ¯ã«è²åãããã253åã®ã¢ããé
žã䞊ã¹ãããŠããããšã瀺ããâ

瞊軞ã¯ãèµ€è²ã®æ²ç·ãã1ãã«è¿ãã»ã©ããªãªã³ã¿ã³ãã¯è³ªã«é¡äŒŒããç¹åŸŽãæã€ããšã瀺ããâ

ããªãªã³ã¿ã³ãã¯è³ªã®ã¢ããé žé åã®äžã§ã倧éã®GXXXGã¢ããŒãã®ãã£ãéšåããã»ãŒã1ãã«ãªã£ãŠããããšã確èªããã
SARS-CoV-2ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªïŒããªãªã³ã¿ã³ãã¯è³ªã®çŽ5åã®ã1273ã¢ããé žãããªãïŒãâ
>YP_009724390.1 surface glycoprotein [Severe acute respiratory syndrome coronavirus 2]
MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
https://www.ncbi.nlm.nih.gov/protein/YP_009724390
ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®äžã«ãGXXXGã¢ããŒãã¯5åãå šäœã«ç¹åšããŠãããâ

PLAACã®è§£æçµæãâ

ããããã®è«æã«æ²èŒãããè§£æçµæãšäžèŽããããšã確èªïŒå·ŠäžïŒãâ

ïŒç»åïŒhttps://www.preprints.org/manuscript/202003.0422/v1ïŒ
ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®å é ããæ°ããŠçŽ500åç®ã®ã¢ããé žåšèŸºã«å°ããªããŒã¯ãèŠãããâ

ããããªãããããã«GXXXGã¢ããŒãã¯ååšããªããâ

ã¹ãã€ã¯ã¿ã³ãã¯è³ªã«ããããããªãªã³ã¿ã³ãã¯è³ªãšã®é¡äŒŒæ§ããšãGXXXGã¢ããŒããã¯ãç¡é¢ä¿ã
SARS-CoV-2ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªïŒSïŒã¯ããŠã€ã«ã¹ç²å衚é¢ã®èã«æ¿ãã£ããèã¿ã³ãã¯è³ªããšåŒã°ããçš®é¡ã®ã¿ã³ãã¯è³ªã

ïŒç»åïŒhttps://www.cas.org/ja/resource/blog/covid-19-spike-proteinïŒ
ãçåããããæ¬æ¥æã€äŒŒããããªå€§ããã®èã¿ã³ãã¯è³ªã§ã¯ãã©ã®ãããªè§£æçµæã«ãªããïŒ
ãäžç®æé·å åå容äœïŒEGFRïŒepidermal growth factor receptorïŒãã¯ãäžç®çްèç³»ãéè现èç³»ãç¥çµçްèç³»ãªã©ã®å šèº«ã®çްèã§çºçŸããŠããããããããµããèã¿ã³ãã¯è³ªã

ïŒç»åïŒhttps://www.proteinatlas.org/ENSG00000146648-EGFR/tissueïŒ
现èèäžã®EGFRã«ãäžç®æé·å åEGFïŒçºèŠè
ã§ããã¹ã¿ã³ãªãŒã»ã³ãŒãšã³ã¯ã1986幎ã«ããŒãã«ççåŠã»å»åŠè³åè³ïŒããçµåãããšã现èã®å¢æ®ãä¿é²ãããããšãç¥ãããŠãããïŒEGFã¯ãã¢ã³ããšã€ãžã³ã°æåãšããŠäžéšã®åç²§åã«å«ãŸãããïŒ

ïŒç»åïŒhttps://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/316b23d2-7568-4871-b050-c9904487bb80/fx1.jpgïŒ
ãŸããEGFRéºäŒåã«å€ç°ãçãããšãEGFãçµåããªããŠãæåžžçã«çްèã®å¢æ®ãä¿é²ããããããçºçãããããªããšèããããŠãããïŒèºããæ£è ã®çŽåæ°ã§ããã®EGFRéºäŒåã®å€ç°ã確èªãããŠãããïŒ
EGFRã¯1978幎ã«åããŠåå®ããããã以æ¥ãéåžžã«ããç ç©¶ãããŠããã¿ã³ãã¯è³ªã
ããäžç®æé·å åå容äœEGFRïŒ1210ã¢ããé žãããªãïŒãâ
>NP_005219.2 epidermal growth factor receptor isoform a precursor [Homo sapiens]
MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA
https://www.ncbi.nlm.nih.gov/protein/NP_005219.2
EGFRã®äžã«ãGXXXGã¢ããŒãã¯4åãâïŒã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯5åãïŒ

PLAACã®è§£æçµæãâ

å é ããæ°ããŠçŽ1100åç®ã®ã¢ããé žåšèŸºã«ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãšåçšåºŠã®ããŒã¯ãèŠããããããã«ãGXXXGã¢ããŒãã¯ååšããªããâ

ããªãªã³ç
ã¯ããæ¥µããŠçšãªçŸæ£ãã
2. ãã®ç æ°ã®æ£è ããã¯ã©ã®ãããããã®ã§ãã
ãã®ç æ°ã®æ£è ããã¯ã幎é100äžäººã«ãããïŒäººããããŸããå¹³æ29幎床æ«ã®é£ç ç»é²è æ°ã¯414åã§ããããåœã® ãµãŒãã€ã©ã³ã¹ ã§ã¯æ¯å¹Ž100åãã200åã®çºç ã確èªãããŠããŸãã
https://www.nanbyou.or.jp/entry/80
çµè«ïŒPLAACãçšããè§£æã§æããã«ãªã£ããSARS-CoV-2ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªããšãããªãªã³ã¿ã³ãã¯è³ªããšã®é¡äŒŒæ§ã¯ããEGFRããšããäžè¬çãªããã¿ã³ãã¯è³ªã«ãèŠåºãããã
---
å人çãªèŠè§£ïŒEGFRã®è§£æçµæã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã®PLAACãçšããè§£æææ³ãšããã®çµæã®è§£éã«åé¡ãããå¯èœæ§ã瀺åããŠããã
ç§åŠå®éšã«ããããããžãã£ãã»ã³ã³ãããŒã«ïŒïŒããªãªã³ïŒããšããã¬ãã£ãã»ã³ã³ãããŒã«ïŒïŒEGFRïŒãã®éèŠæ§ã«ã€ããŠãèããããããå
容ã®è«æã§ãã£ããšæãã
---
6/16远èšïŒæšæ¥ããè§£åå®ç¿éºäœããããªãªã³ããšããã¿ã€ãã«ã®èšäºããYahoo!ãã¥ãŒã¹ãªã©ã®è€æ°ã®å€§æã¡ãã£ã¢ãäžæã«å ±ããŸããã
ããã«ãããTwitterã§ã¯ãã¯ã¯ãã³æ¥çš®ãåå ã§ã¯ïŒããšããããšã話é¡ã«ãªã£ãŠããããã§ãã
ããããç§åŠé¢é£ã®èšäºãèŠãããå¿ ãåèè«æããè±èªãèŠæãªæ¹ã¯ã倧åŠã®ãã¬ã¹ãªãªãŒã¹ããã§ãã¯ããããã«ããŠãã ãããïŒèšäºäžã«çŽãªã³ã¯ã®ãªãèšäºã¯ãç§ã¯ä¿¡çšããŠããŸãããïŒ
é·åŽå€§åŠã®ãã¬ã¹ãªãªãŒã¹ã¯ãã¡ããâ
åèè«æã¯ãã¡ããâ
è«æã«ã¯ãç°åžžåããªãªã³ã¿ã³ãã¯è³ªïŒPrPSCïŒãæ€åºããã埡éºäœã«ã€ããŠã®æ
å ±ãæžãããŠããŸãã
This donor, who had died 8 years earlier at 92 years of age, had resided in a nursing home and had no surviving relatives from whom we could obtain a medical or family history.
èš³ïŒãã®ãããŒã®æ¹ã¯8幎åã«92æ³ã§äº¡ããªããŸããããè人ããŒã ã«å ¥å± ããŠãããç æŽãå®¶ææŽãç¥ãããšã®ã§ããéºæã¯ããŸããã§ããã
https://www.nejm.org/doi/full/10.1056/NEJMc2204116?query=featured_home
2021幎床ã®äººäœè§£åå®ç¿ã«çšããããã«ãæäŸããã ãã埡éºäœã§ããã8幎åã«äº¡ããªãããæ¹ã®åŸ¡éºäœã§ããæ°åã³ããã¯ã¯ãã³ãšç¡é¢ä¿ã§ããããšã¯æããã§ãã